Metformin was found to impact cystogenesis in preclinical models of polycystic disease, is generally considered safe and may be a promising candidate for clinical investigation in ADPKD. In this phase 2 two-year trial, we randomly assigned 97 patients, 18-60 years of age, with ADPKD and ...
Barzilai N, Kritchevsky S, Espeland M, Crandall J. Targeting aging with metformin (tame): A study to target aging in humans. The Gerontologist. 2016;56:199Barzilai N, Kritchevsky S, Espeland M, Crandall J. Targeting aging with metformin (tame): A study to target aging in humans. ...